Rabbit Anti-Human VEGFR-2/KDR (Peptide), soluble
Slide this table
| Cat-Nr. | 102-PA19 |
| Size | 200 µg |
| Price | 305 € |
| Category | Polyclonal Antibody |
| Clone Nr. | Rabbit IgG |
| Species Reactivity | Human |
| Formulation | lyophilized |
| Buffer | PBS |
| Reconstitution | Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml. |
| Stability and Storage | The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots. |
| Preparation | Produced from sera of rabbits immunised with a peptide of the C-terminal end of native human soluble VEGFR-2/KDR (CGRETILDHSAEAVGMP). Anti-human soluble VEGFR-2/KDR was purified by affinity chromatography with immobilized Protein A. |
| Antigen | Peptide: CGRETILDHSAEAVGMP. |
| Application | WB |
| Synonyms | soluble vascular endothelial growth factor receptor-2 ; soluble KDR; soluble FLK1; soluble CD309; VEGF receptor 2; sKDR |
| Description | VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. Human VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis. |
| Uniprot ID | P35968 |
| Protein RefSeq | NP_002244.1 |
| mRNA RefSeq | NM_002253.2 |
Figures
Western Blot Analysis of anti-human esKDR. Samples were loaded in 10% SDS-polyacrylamide gel under reducing conditions.
Left panel: monoclonal antibody against the soluble KDR D1-7); Right panel: polyclonal antibody (peptide) against against the unique C-terminal end of esKDR.
Immunofluorescence staining with consecutive sections of unfixed, human foreskin. A) Staining with anti-sVEGFR2/KDR antibodies (#102-PA19). Note signal in epidermis and vessels. B) Staining with anti-membrane-bound VEGFR-2/KDR (#101-M32). Note staining in vessels. C) Negative control. Note non-specific fluorescence in the hornified layer of the epithelium.
Provided by Prof. J. Wilting, Göttingen, Germany.
All prices plus VAT + possible delivery charges